Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Damelin

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Journal of Molecular Biology|February 23, 2013
Comprehensive interrogation of a minimalist synthetic CDR-H3 library and its ability to generate antibodies with therapeutic potentialCiara M Mahon, Matthew A Lambert, Jacob Glanville, et al.
Journal of Medicinal Chemistry|July 24, 2023
Discovery and Optimization of a STING Agonist Platform for Application in Antibody Drug ConjugatesJeremy R Duvall, Joshua D Thomas, Raghida A Bukhalid, et al.
Molecular Cancer Therapeutics|February 14, 2024
Development of a Novel DNA Mono-alkylator Platform for Antibody-Drug ConjugatesJoshua D Thomas, Aleksandr V Yurkovetskiy, Mao Yin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2025
XMT-2056, a HER2-Directed STING Agonist Antibody-Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune CellsRaghida A Bukhalid, Jeremy R Duvall, Kelly Lancaster, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2015
Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor RegressionsMarc Damelin, Alexander Bankovich, Albert Park, et al.
Molecular Cancer Therapeutics|September 29, 2023
Site-Specific Dolasynthen Antibody-Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody RatiosSusan M Clardy, Alex Uttard, Bingfan Du, et al.
Cancer Research|May 5, 2011
Delineation of a cellular hierarchy in lung cancer reveals an oncofetal antigen expressed on tumor-initiating cellsMarc Damelin, Kenneth G Geles, Maximillian T Follettie, et al.
Science Translational Medicine|January 13, 2017
A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressionsMarc Damelin, Alexander Bankovich, Jeffrey Bernstein, et al.
Molecular Cancer Therapeutics|June 9, 2023
Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of CancerDorin Toader, Shawn P Fessler, Scott D Collins, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Journal of Molecular Biology|February 23, 2013
Comprehensive interrogation of a minimalist synthetic CDR-H3 library and its ability to generate antibodies with therapeutic potentialCiara M Mahon, Matthew A Lambert, Jacob Glanville, et al.
Journal of Medicinal Chemistry|July 24, 2023
Discovery and Optimization of a STING Agonist Platform for Application in Antibody Drug ConjugatesJeremy R Duvall, Joshua D Thomas, Raghida A Bukhalid, et al.
Molecular Cancer Therapeutics|February 14, 2024
Development of a Novel DNA Mono-alkylator Platform for Antibody-Drug ConjugatesJoshua D Thomas, Aleksandr V Yurkovetskiy, Mao Yin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2025
XMT-2056, a HER2-Directed STING Agonist Antibody-Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune CellsRaghida A Bukhalid, Jeremy R Duvall, Kelly Lancaster, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2015
Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor RegressionsMarc Damelin, Alexander Bankovich, Albert Park, et al.
Molecular Cancer Therapeutics|September 29, 2023
Site-Specific Dolasynthen Antibody-Drug Conjugates Exhibit Consistent Pharmacokinetic Profiles across a Wide Range of Drug-to-Antibody RatiosSusan M Clardy, Alex Uttard, Bingfan Du, et al.
Cancer Research|May 5, 2011
Delineation of a cellular hierarchy in lung cancer reveals an oncofetal antigen expressed on tumor-initiating cellsMarc Damelin, Kenneth G Geles, Maximillian T Follettie, et al.
Science Translational Medicine|January 13, 2017
A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressionsMarc Damelin, Alexander Bankovich, Jeffrey Bernstein, et al.
Molecular Cancer Therapeutics|June 9, 2023
Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of CancerDorin Toader, Shawn P Fessler, Scott D Collins, et al.
Pageof 3